Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
With TRIUMPH-1 running another 12 weeks longer (80 vs 68) in a healthier general-obesity population, the directional expectation is clear: the headline number should be higher than 28.7%
Research is continuously investigating new multi-receptor agonists that may provide improved therapeutic advantages while ensuring acceptable safety profiles
Despite the friction, the partnership could be mutually beneficial
It is also approved for children aged 12 and older with obesity
Its older counterparts GLP-1 agonist like Semaglutide and dual agonist Tirzepatide have made their way in weight loss and diabetes research
Lam CSP, Ramasundarahettige C, Branch KRH et al (2022) Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial
US$ 29.94
US$ 23.04
US$ 26.22
US$ 24.33
